Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to $374.1.

  • ProQR Therapeutics' Shares Outstanding (Weighted Average) rose 4810.44% to $374.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $374.1, marking a year-over-year increase of 4810.44%. This contributed to the annual value of $93.2 million for FY2024, which is 632.56% up from last year.
  • Latest data reveals that ProQR Therapeutics reported Shares Outstanding (Weighted Average) of $374.1 as of Q3 2025, which was up 4810.44% from $237.71 recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics' Shares Outstanding (Weighted Average) registered a high of $92.0 million during Q4 2024, and its lowest value of $97.77 during Q1 2024.
  • In the last 5 years, ProQR Therapeutics' Shares Outstanding (Weighted Average) had a median value of $304.81 in 2023 and averaged $17.1 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first crashed by 5801.33% in 2023, then soared by 6979.95% in 2025.
  • ProQR Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $73.4 million in 2021, then dropped by 0.45% to $73.1 million in 2022, then rose by 19.25% to $87.2 million in 2023, then rose by 5.54% to $92.0 million in 2024, then crashed by 100.0% to $374.1 in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $374.1 for Q3 2025, versus $237.71 for Q2 2025 and $105.19 for Q1 2025.